CARDIOVASCULAR RISK FACTORS AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Introduction: Patients with prostate cancer (PCa) are less likely to die of prostate cancer than of non-prostate causes such as cardiovascular disease (CVD). Recently, Jakarta Cardiovascular Risk score prediction models were developed and validated with good reliability in predicting 10-year cardiovascular events in the Indonesian population. Objective: This study aims to describe cardiovascular risk factors among newly diagnosed prostate cancer patients. Material & Methods: This is a cross-sectional, retrospective study of patients with newly diagnosed prostate cancer at Hasan Sadikin Academic Medical Center from 2013 to 2023. The Jakarta CV Risk score was calculated on all populations and among groups according to tumor extension: local (T1-T2), locally advanced (T3-T4), and metastatic. A score of -7 to 1 was considered a low risk for CV event, 2 – 4 was intermediate risk, and >4 was considered high-risk. Results: There were a total of 118 subjects included in this study. The mean age was 67.5 ± 9.7 years, the mean BMI was 22.3 ± 2.79 kg/m2. The average Jakarta cardiovascular score in this population was 7.25 ± 2.24. In the local PCa group (T1-T2) was 6.97 ±1.99 (high risk); in the locally advanced PCa group (T3-T4) was 7.30 ± 1.70 (high risk); and in the metastatic group was 7.14 ± 2.08 (high risk). Unfortunately, there are 22 (19.5%) patients who will be planned to receive Androgen-deprivation therapy based on staging. Conclusion: Patients with newly diagnosed PCa commonly have high cardiovascular risk and it should be our consideration for giving ADT treatment. Keywords: Prostate cancer, cardiovascular disease, Jakarta cardiovascular risk score, androgen-deprivation therapy.
##plugins.themes.bootstrap3.article.details##
Prostate cancer, cardiovascular disease, Jakarta cardiovascular risk score, androgen-deprivation therapy
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
Moningi S, Nguyen PL. Uncontrolled Cardiovascular Risk Factors in Prostate Cancer Patients: Are We Leaving Too Much on the Table? JACC CardioOncol. 2023;5(1):82-4.
American Cancer Society. Cancer Facts and Figures 2022. Atlanta: American Cancer Society. Accessed January 3, 2023.
D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25: 2420–2425.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456.
Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, et al. The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis. JACC CardioOncol. 2023;5(1):70-81.
Kusmana D. The influence of smoking cessation, regular physical exercise and/or physical activity on survival: a 13 years cohort study of the Indonesian population in Jakarta. Med J Indones. 2002;11(4):230-41.
Rawla P. Epidemiology of Prostate Cancer. World Journal of Oncology. 2019;10(2):63-89.
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377-85.
Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023;21:19.
Mahal BA, Berman RA, Taplin, et al. Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. JAMA. 2018;320(23):2479-2481.
Leong DP, Fradet V, Shayegan B, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. J Urol. 2020 Jun;203(6):1109-1116.
Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Network Open. 2021;4(2).
Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9(9):e107516.
Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist. J Urol. 2024;211(1):63-70.
De Nunzio C, Truscelli G, Trucchi A, Petta S, Tubaro M, Gacci M, et al. Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis. Prostate Cancer Prostatic Dis. 2016;19(1):35-9.
Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012;53(9):593-7.
Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185–190.